Not just Holistic, but how to use E: All of the Above!

I made this blog because I did tons of research on success stories and research worldwide and used it on my dog with nasal cancer named Lucy. So, now my hobby is molecular biology. The treatment uses combination of health store supplements, some prescription meds, diet changes, and specific Ayurvedic and Chinese medicinal herbs. I just wanted her to have a better quality of life. I thought this combination of E: All the Above (except no radiation or chemo and surgery for this cancer was not an option) would help that for sure, but it actually put her bleeding nasal cancer in remission!
My approach to cancer is about treating the whole animals biologic system. But I do hate the word 'Holistic'. Sounds like hoo hoo. This is science based, research based data and results of using active herbal compounds that happen to be readily available and common. Some call it Nutriceuticals. Others may call it Orthomolecular cancer therapy. Or Cancer Immunotherapy.
I FEEL DIVERSITY IN TREATMENT IS KEY:
-Slow cancer cell reproduction
-Make cancer cells become easier targets for the immune system
-Kill the cancer cells
-Rid the cancer cells
-Remove the toxins it produces
- Stimulate and Modulate the immune system
-Control secondary symptoms like bleeding, infection, inflammation, mucous, appetite, or pain for a better feeling animal
-Working with your vet for exams and prescriptions that are sometimes needed when conditions are acute.
Just by using a multi-modal treatment approach that is as diverse in attack as possible. Both conventional and natural.
The body conditions that allowed it to develop in the first place must be corrected. If caught early enough, like with Lucy, this ongoing maintenance correctional treatment is all that was required at this point to achieve, so far, more than 10 TIMES the life expectancy given (more than 60 months) after diagnosis WITH remission. I did not use radiation or chemotherapy or surgery.
I hope this cancer research can help your dog as well.

My Lucy

My Lucy
In Loving Memory my Lucy December 2016
CURRENT STATUS - It was for more than 5 YEARS after Lucy was diagnosed by biopsy in March 2011 with nasal cancer that she lived. And she was in remission for 4 of 5 years using no radiation or chemo! Now multiply that by 7 to be 35 years extended!! She was 12.5 years old - equivalent to almost 90 human years old. She ended her watch December 1, 2016. I miss her so much.

March 28, 2014

Soy-Derived Isoflavones like GENISTEIN Inhibit the Growth of Canine Cancers



Soy May Aid In Treating Canine Cancers
Apr. 11, 2009 — Researchers at North Carolina State University are looking to soy as a way to make traditional canine cancer therapy more effective, less stressful for the dog and less costly for the owners.
Dr. Steven Suter, assistant professor of oncology, and NC State colleagues studied genistein - a molecule found in soy that has been shown to be toxic to a wide variety of cancer cells in humans - to determine whether it would also inhibit the growth of canine lymphoma cells.
The researchers found that a commercially available form of genistein called GCP was effective in killing canine lymphoid cells in a laboratory setting, and that GCP is "bioavailable" in canines - meaning it is absorbed into the bloodstream where it can affect cancer cells in the body. The researchers hope that their findings will lead to the use of GCP for their canine patients in conjunction with traditional cancer treatments like chemotherapy.
The researchers' findings were published in Clinical Cancer Research.
"Humans have been using soy in conjunction with traditional chemotherapy for some time as a chemo potentiator," Suter says. "This means that the GCP makes the chemotherapy work more efficiently and faster, which translates to less stress on the patient and less money spent on chemotherapy."
Since dogs absorb GCP in much the same way that humans do, Suter hopes that veterinarians will be able to offer this therapy to canine patients in the near future.
"Since GCP is a dietary supplement, it is harmless to patients," he adds. "Plus it's inexpensive and easy to administer in a pill form. There's really no downside here."


Soy-Derived Isoflavones Inhibit the Growth of Canine Lymphoid Cell Lines

-GENISTEIN supplements ( google it as canine lymphoma genistein and see what comes up). Genistein is an isoflavone extracted from soybeans. If you google it you'll find page after page of promising research -- especially on lymphoma and t-cell lymphoma. Among other things it caused the death of cancer cells without harming healthy ones. (Something chemo or radiation DON"T do)
I found one source so far that is pure genistein costs alot but it is pure and likely near what researchers use due to dosage and pureness
Swanson now carries one. Yay! Cheaper!




Here is one article:


  1. Vahbiz Jamadar-Shroff1,
  2. Mark G. Papich2 and
  3. Steven E. Suter1
+ Author Affiliations


  1. Authors' Affiliations: Departments of 1Clinical Sciences and 2Molecular and Biomedical Sciences, North Carolina State College of Veterinary Medicine, Raleigh, North Carolina

  1. Requests for reprints:
    Steven E. Suter, North Carolina State College of Veterinary Medicine, 4700 Hillsborough Street, CVM Research Building #308, Raleigh, NC 27606. Phone: 919-513-0813; Fax: 919-513-7301; E-mail: 

 Abstract

Purpose: This study aimed to evaluate the in vitro effects of genistein, both pure genistein and a commercially available form of genistein called Genistein Combined Polysacharride (GCP), against two canine B-cell lymphoid cell lines and determine the oral bioavailability of GCP when fed to normal dogs.

Experimental Design: The in vitro effect of genistein and GCP was evaluated using cell proliferation and apoptotic assays. The IC50 of both compounds was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay and propidium idodide staining. Apoptosis was evaluated using Annexin V staining, caspase 3 and 9 staining, and DNA laddering. Cell cycle analysis and Bcl-2/Bax ratios were also examined. An initial dose escalating pharmacokinetic study was used to determine if therapeutic serum levels of genistein could be reached with oral dosing of GCP in normal dogs.

Results: The 72-hour in vitro IC50 of genistein and GCP against the GL-1 and 17-71 cells were both 10 μg/mL and 20 μg/mL, respectively. GCP led to cell death in both cell lines via apoptosis and treated cells exhibited increased Bax:Bcl-2 ratios. The serum concentrations of genistein in normal dogs given increasing oral doses of GCP did not reach the 72-hour in vitro IC50 in a dose escalation study.

Conclusions: The results of these studies support the notion that canine high-grade B-cell lymphoma may represent a relevant large animal model of human non-Hodgkin's lymphoma to investigate the utility of GCP in chemopreventive and/or treatment strategies that may serve as a prelude to human clinical lymphoma trials.

Translational Relevance

Canine lymphoma has historically been considered an excellent animal model of a variant of human non-Hodkin's lymphoma called diffuse, large B-cell lymphoma. Dogs are large, long-lived animals that are evolutionarily more closely related to humans than rodents; therefore, they represent an accessible, spontaneous population of high-grade lymphomas occurring in immunocompetent animals. Based on a large body of human literature documenting the antiproliferative effects of genistein, we hypothesized that genistein would also have in vitro activity against canine lymphoid cell lines and perhaps in vivo activity in canine lymphoma patients in either chemopreventive or treatment protocols. The results presented here support our hypothesis that genistein has significant in vitro antiproliferative activity against two well-established canine B-cell lines, mirroring human cell line data. Additionally, we developed an extremely sensitive high-pressure liquid chromatography–based assay to detect plasma genistein in dogs fed a commercially made, highly bioavailable form of genistein called Genistein Combined Polysacharride (GCP). With this assay, we were able to show that genistein in GCP can be absorbed by canine gut enterocytes, which leads to detectable genistein plasma levels. These initial studies with GCP lay the groundwork for future studies in the setting of canine lymphoma with findings that may be directly applicable to human diffuse large B-cell lymphoma. 

Genistein (4, 5, 7-trihydroxyisoflavone) is a readily available isoflavone found in soy-based products. Epidemiologic studies indicate that consumption of soy-containing diets is associated with a lower incidence of many human tumors (1, 2). Genistein has been identified as an inhibitor of various protein tyrosine kinases that play a role in cell growth and apoptosis, including camp-responsive element-binding protein (3), signal transducers and activators of transcription (4), members of the fork-head-related transcription factors (5), and nuclear factor κB (NF-κB; ref. 6). At pharmacologic concentrations genistein's recorded activities also include topoisomerase I and II inhibition (7), antioxidant activity (8), induced differentiation (9), and deregulation of mitochondrial membrane pore permeability (10). 

Genistein's effects on various human solid cancer cell lines have been extensively studied (11). Although the precise molecular mechanisms responsible for these activities are not clearly understood, the compound can inhibit cancer cell growth (12, 13), induce apoptotic cell death with cell cycle arrest at G2-M phase, and inhibit angiogenesis (14). Genistein causes epigenetic changes in mouse prostate (15) and up-regulates mRNA expression of the BRCA1 tumor suppressor gene during mammary tumorigenesis (16). The compound also inhibits DNA methyltransferase and reverses the methylation status, with concomitant reexpression, of the p16INK4a, RARb, and MGMT genes in human esophageal squamous cell carcinoma and prostate cell lines (17).

Genistein is also active against human lymphoid neoplasia (18, 19). Genistein induces apoptosis via mitochondrial damage in T lymphoma cells (20) and via Akt signaling in anaplastic large-cell lymphoma (21). The molecule also reduces NF-κb in T lymphoma cells via caspase-mediated cleavage of Iκβα (22). Finally, when included into a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) lymphoma protocol, genistein has growth modulatory effects, via G2-M arrest and decreased NF-κb binding, in a diffuse large B-cell lymphoma xenograft setting (23). 

Natural and synthetic genistein glycosides are not easily absorbed across enterocytes in humans and cats (24, 25). Genistein Combined Polysacharride (GCP), a commercially available form of genistein (26), is a complex mixture produced by fermentation of soybean extracts with a mushroom mycelia (Ganoderma lucidum) culture that contains approximately 40% isoflavones. Fermentation deglycosylates soy isoflavones, producing aglycone isoflavones that are highly absorbable across the gut lumen (27). GCP has documented in vitro and in vivo effects on a wide variety of human cancers (28, 29). 

Case reports show complete regression of T3 prostate cancer following treatment with GCP (7); and supplementation with GCP prevented recurrence of transitional cell carcinoma (TCC) of the bladder (10).

Canine high-grade B-cell lymphoma, which is similar phenotypically and biologically to the most common variant of human non-Hodgkin's lymphoma called diffuse large B-cell lymphoma, is one of the most common malignant tumors of dogs (up to 25% of all cancers) and it is the most common hematopoietic tumor of the dog (83%; ref. 30). The median survival time of canine B-cell lymphoma patients treated with CHOP or L-VCAP (asparaginase, vincristine, cyclophosphamide, adriamycin, prednisone)-based protocols is 12 to 14 months, with an overall cure rate of <10% (31). Dogs are evolutionarily more closely related to humans than rodents and are large, long-lived animals; therefore, canine B-cell lymphoma represents an excellent model to investigate novel therapeutics and treatment strategies that may have direct applicability to the human disease (32). 

Based on the similarity between canine B-cell lymphoma and human diffuse large B-cell lymphoma, we hypothesized that genistein would inhibit the cell growth of two well-established canine lymphoid B-cell lines. We show that genistein induces cell death via apoptosis at concentrations similar to those reported in the human literature. We also present our preliminary findings of the oral absorption of GCP in domestic dogs.



Soy-derived isoflavones inhibit the growth of canine lymphoid cell ...
by V Jamadar-Shroff - 2009 - Cited by 17 - Related articles
Feb 15, 2009 - EXPERIMENTAL DESIGN: The in vitro effect of genistein and GCP was ... the notion that canine high-grade B-celllymphoma may represent a ...










**I will be starting genistein on Lucy's cancer on about 4/1/2014.  She was diagnosed in 4/2011 and has been taking the Tippner Protocol. I am adding a few new things because while she was in remission using only the pills on the Tippner cancer protocol, she has become stuffy again on the left side. Cancer can adapt and so must the protocol if needed. I will be adding genestein, luteolin, and apigen. I will have a research post on the luteolin and apigen soon.  The GCP version of genestein, I am still looking for a source.
Swanson now carries one. Yay! Cheaper!





I buy most of the stuff from Swanson Vitamins. They are cheaper, in capsules for dosage changes, and carry almost everything I give to Lucy except for the Chinese Herbs Stasis Breaker prescription, and the Low Dose Naltrexone prescription. Here is a $5 off coupon link I found
Posted by Unknown at 9:58 AM
Labels: , , ,